SMO ClinPlus Co. Ltd. - Asset Resilience Ratio
SMO ClinPlus Co. Ltd. (301257) has an Asset Resilience Ratio of 15.78% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how SMO ClinPlus Co. Ltd.'s Asset Resilience Ratio has changed over time. See SMO ClinPlus Co. Ltd. (301257) flexibility index to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down SMO ClinPlus Co. Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SMO ClinPlus Co. Ltd. market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥240.57 Million | 15.78% |
| Total Liquid Assets | CN¥240.57 Million | 15.78% |
Asset Resilience Insights
- Good Liquidity Position: SMO ClinPlus Co. Ltd. maintains a healthy 15.78% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
SMO ClinPlus Co. Ltd. Industry Peers by Asset Resilience Ratio
Compare SMO ClinPlus Co. Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ICON Public Limited Company
F:IJF |
Diagnostics & Research | 0.00% |
|
Fleury S.A.
SA:FLRY3 |
Diagnostics & Research | 16.06% |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Diagnósticos da América S.A
SA:DASA3 |
Diagnostics & Research | 10.42% |
|
Cowealth Medical China Co.Ltd.
SHG:603122 |
Diagnostics & Research | 2.25% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Cytogen Inc
KQ:217330 |
Diagnostics & Research | 32.97% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
Annual Asset Resilience Ratio for SMO ClinPlus Co. Ltd. (2022–2025)
The table below shows the annual Asset Resilience Ratio data for SMO ClinPlus Co. Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 9.74% | CN¥150.31 Million ≈ $21.99 Million |
CN¥1.54 Billion ≈ $225.92 Million |
-18.28pp |
| 2024-12-31 | 28.02% | CN¥400.58 Million ≈ $58.62 Million |
CN¥1.43 Billion ≈ $209.20 Million |
-2.79pp |
| 2023-12-31 | 30.81% | CN¥421.14 Million ≈ $61.63 Million |
CN¥1.37 Billion ≈ $200.01 Million |
+19.06pp |
| 2022-12-31 | 11.75% | CN¥136.38 Million ≈ $19.96 Million |
CN¥1.16 Billion ≈ $169.85 Million |
-- |
About SMO ClinPlus Co. Ltd.
SMO ClinPlus CO.,LTD. provides site management services in research development in pharmaceuticals, medical devices, and health-related products in China. The company offers early modeling, preliminary preparation plan trial site initiation, on-site execution, and project management services. SMO ClinPlus CO.,LTD. was founded in 2009 and is based in Shanghai, China.